Drugs / IMM-1-104
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05585320 | Oct 2022 → Jun 2026 overdue | cutaneous melanoma, non-small cell lung carcinoma, pancreatic adenocarcinoma | Immuneering Corporation | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM-1-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05585320 ↗ |
| Action | Inhibit | “a Novel Oral Dual MEK1/2 Inhibitor” NCT05585320 ↗ |
| Route | Oral | “Once-daily, oral IMM-1-104 dose” NCT05585320 ↗ |